AORT · Insider Trading
Artivion, Inc.
Every open-market purchase and sale reported by AORT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-11 | Andrew M Green | SVP, Regulatory and Quality | Sell | −11,480 | −$286.66K |
| 2026-09-04 | Andrew M Green | SVP, Regulatory and Quality | Sell | −8,003 | −$216.34K |
| 2026-08-20 | James P Mackin | President & CEO | Sell | −70,000 | −$2.03M |
| 2026-08-17 | Lance A Berry | EVP, COO, CFO & Treasurer | Sell | −715 | −$20.41K |
| 2026-08-17 | Andrew M Green | SVP, Regulatory and Quality | Sell | −616 | −$17.59K |
| 2026-08-12 | Jean F Holloway | SVP, General Counsel | Sell | −977 | −$27.83K |
| 2026-06-15 | Andrew M Green | SVP, Regulatory and Quality | MIXED | — | −$321.66K |
| 2026-06-04 | Anthony B. Semedo | Director | J | — | — |
| 2026-05-20 | Elizabeth A Hoff | Director | A | +7,576 | — |
| 2026-05-20 | James Bullock | Director | A | +7,576 | — |
| 2026-05-20 | Marna P Borgstrom | Director | A | +7,576 | — |
| 2026-05-20 | Jon W Salveson | Director | A | +7,576 | — |
| 2026-05-20 | Jeffrey H Burbank | Director | A | +7,576 | — |
| 2026-05-20 | Thomas F Ackerman | Director | A | +7,576 | — |
| 2026-05-20 | Daniel J Bevevino | Director | A | +7,576 | — |
| 2026-05-20 | Anthony B. Semedo | Director | A | +7,576 | — |
| 2026-05-19 | Marna P Borgstrom | Director | A | +7,850 | — |
| 2026-03-04 | Amy Horton | VP, Chief Accounting Officer | MIXED | +6,574 | −$34.04K |
| 2026-03-04 | Lance A Berry | EVP, COO, CFO & Treasurer | MIXED | +34,558 | −$238.59K |
| 2026-03-04 | John E Davis | Chief Commercial Officer | MIXED | +24,272 | −$172.75K |
| 2026-03-04 | James P Mackin | President & CEO | MIXED | +99,061 | −$675.69K |
| 2026-03-04 | Marshall S. Stanton | SVP, Clinical & MD Affair | MIXED | +19,689 | −$81.18K |
| 2026-03-04 | Jean F Holloway | SVP, General Counsel | MIXED | +14,990 | −$485.73K |
| 2026-03-03 | Lance A Berry | EVP, COO, CFO & Treasurer | Sell | −5,178 | −$196.89K |
| 2026-03-03 | Marshall S. Stanton | SVP, Clinical & MD Affair | Sell | −1,513 | −$57.53K |
| 2026-03-03 | John E Davis | Chief Commercial Officer | Sell | −2,784 | −$105.86K |
| 2026-03-03 | Amy Horton | VP, Chief Accounting Officer | Sell | −641 | −$24.37K |
| 2026-03-03 | Jean F Holloway | SVP, General Counsel | Sell | −2,183 | −$83.01K |
| 2026-03-03 | James P Mackin | President & CEO | Sell | −14,911 | −$566.99K |
| 2026-02-25 | James P Mackin | President & CEO | MIXED | +62,132 | −$1.29M |
| 2026-02-25 | Marshall S. Stanton | SVP, Clinical & MD Affair | Sell | −3,682 | −$136.01K |
| 2026-02-25 | Amy Horton | VP, Chief Accounting Officer | MIXED | +3,097 | −$94.69K |
| 2026-02-25 | Jean F Holloway | SVP, General Counsel | MIXED | +15,338 | −$175.27K |
| 2026-02-25 | John E Davis | Chief Commercial Officer | MIXED | +14,590 | −$215.88K |
| 2026-02-25 | Lance A Berry | EVP, COO, CFO & Treasurer | MIXED | +28,016 | −$347.31K |
| 2025-12-17 | John E Davis | Chief Commercial Officer | Sell | −5,000 | −$225.55K |
| 2025-12-09 | Amy Horton | VP, Chief Accounting Officer | Sell | −4,572 | −$203.08K |
| 2025-12-04 | James P Mackin | President & CEO | MIXED | — | −$489.82K |
| 2025-12-04 | Jean F Holloway | SVP, General Counsel | Sell | −7,315 | −$331.37K |
| 2025-12-03 | James P Mackin | President & CEO | MIXED | — | −$492.85K |
| 2025-12-02 | Amy Horton | VP, Chief Accounting Officer | G | −750 | — |
| 2025-11-24 | Marshall S. Stanton | SVP, Clinical & MD Affair | MIXED | — | −$1.46M |
| 2025-11-24 | Marshall S. Stanton | SVP, Clinical & MD Affair | MIXED | −11,888 | −$622.39K |
| 2025-11-19 | Elizabeth A Hoff | Director | Sell | −4,200 | −$189.41K |
| 2025-11-18 | Jean F Holloway | SVP, General Counsel | MIXED | — | −$197.75K |
| 2025-11-18 | John E Davis | Chief Commercial Officer | MIXED | — | −$195.64K |
| 2025-11-18 | Amy Horton | VP, Chief Accounting Officer | Sell | −6,000 | −$274.38K |
| 2025-11-14 | John E Davis | Chief Commercial Officer | Sell | −6,563 | −$300.97K |
| 2025-11-14 | Jean F Holloway | SVP, General Counsel | Sell | −5,761 | −$264.19K |
| 2025-11-14 | James P Mackin | President & CEO | Sell | −34,210 | −$1.57M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James P Mackin | President & CEO | 877,275 | $19.60M |
| John E Davis | Chief Commercial Officer | 230,794 | $5.16M |
| Lance A Berry | EVP, COO, CFO & Treasurer | 210,112 | $4.69M |
| Jean F Holloway | SVP, General Counsel | 184,118 | $4.11M |
| Daniel J Bevevino | Director | 157,637 | $3.52M |
| Thomas F Ackerman | Director | 157,472 | $3.52M |
| Amy Horton | VP, Chief Accounting Officer | 139,088 | $3.11M |
| Jon W Salveson | Director | 137,416 | $3.07M |
| James Bullock | Director | 76,223 | $1.70M |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 62,246 | $1.39M |
| Jeffrey H Burbank | Director | 61,372 | $1.37M |
| Marna P Borgstrom | Director | 56,664 | $1.27M |
| Anthony B. Semedo | Director | 41,235 | $921.19K |
| Andrew M Green | SVP, Regulatory and Quality | 40,160 | $897.17K |
| Elizabeth A Hoff | Director | 34,765 | $776.65K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AORT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.